All In Biotech

Drug Trial Radar · NCT02437591

Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Aug 13, 2015

Primary completion

May 12, 2016

Study completion Oct 24, 2016

Sponsor

Lead sponsor
Astellas Pharma Europe Ltd.Astellas (ALPMY)
Sponsor type
Industry
First posted
May 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the plasma pharmacokinetics (PK) of fidaxomicin (FDX) and primary metabolite OP-1118 in Subjects with Inflammatory Bowel Disease (IBD) and C. difficile Infection (CDI). This study will also compare CDI clinical response to the microbiological response in terms of magnitude of reduction of C. difficile total viable count and spore count during treatment with FDX and if achieved; the time to microbial eradication; determine time to negative CDI toxin assay in stool specimens during treatment with FDX; assess the stool concentrations of FDX and metabolite OP-1118 throughout therapy; assess the length of hospital stay, readmissions and resource utilization for IBD patients receiving FDX; record the incidence and severity of Adverse Events (AEs) and document the impact of treatment on Quality of Life as measured by the changes in Short Inflammatory Bowel Disease Questionnaire (IBDQ) score.

Conditions

  • Inflammatory Bowel Disease (IBD)
  • Clostridium Difficile Infection (CDI)

Interventions

  • fidaxomicinDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic parameter of fidaxomicin: Maximum plasma concentration (Cmax)Time frame: Day 1, Day 5 and Day 10
  2. Pharmacokinetic parameter of OP-1118: Maximum plasma concentration (Cmax)Time frame: Day 1, Day 5 and Day 10
  3. Pharmacokinetic parameter of fidaxomicin: Area under the curve from 0 to 12 hrs (AUC12)Time frame: Day 1
  4. Pharmacokinetic parameter of OP-1118: Area under the curve from 0 to 12 hrs (AUC12)Time frame: Day 1
  5. Pharmacokinetic parameter of fidaxomicin and OP-1118: Metabolite to Parent Ratio (MPR)Time frame: Day 1
  6. Pharmacokinetic parameter of fidaxomicin: Area under the concentration-time curve from the time of dosing to the start of the next dosing interval (AUCtau)Time frame: Day 5 and Day 10
  7. Pharmacokinetic parameter of OP-1118: Area under the concentration-time curve from the time of dosing to the start of the next dosing interval (AUCtau)Time frame: Day 5 and Day 10
  8. Pharmacokinetic parameter of fidaxomicin: The time after dosing when Cmax occurs (tmax)Time frame: Day 1, Day 5 and Day 10
  9. Pharmacokinetic parameter of OP-1118: The time after dosing when Cmax occurs (tmax)Time frame: Day 1, Day 5 and Day 10
  10. Pharmacokinetic parameter of fidaxomicin: Apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F)Time frame: Day 5 and Day 10
  11. Pharmacokinetic parameter of OP-1118: Apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F)Time frame: Day 5 and Day 10
  12. Pharmacokinetic parameter of fidaxomicin: Concentration immediately prior to dosing at multiple dosing (Ctrough)Time frame: Day 5 and Day 10
  13. Pharmacokinetic parameter of OP-1118: Concentration immediately prior to dosing at multiple dosing (Ctrough)Time frame: Day 5 and Day 10

Locations

12 sites in 7 countries. Site status is shown where the registry gives one.

  • Site AT43001

    Graz, Austria

  • Site FR33002

    Clichy, France

  • Site FR33001

    Paris, France

  • Site GR30004

    Athens, Greece

  • Site IT39003

    Padova, Italy

  • Site IT39001

    Roma, Italy

  • Site PL48002

    Warsaw, Poland

  • Site PL48003

    Warsaw, Poland

  • Site RU70003

    Moscow, Russia

  • Site RU70002

    Moscow, Russia

  • Site RU70001

    Saint Petersburg, Russia

  • Site GB44002

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.